The role of plasma adenosine deaminase in chemoattractant-stimulated oxygen radical production in neutrophils

European Journal of Cell Biology

Volumn 89, Issue 6, 2010, Pages 462-467

  Kälvegren, Hanna ^a,b   Fridfeldt, Jonna ^a   Bengtsson, Torbjörn ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Adenosine A1 receptor antagonist; Adenosine deaminase; Inflammation; Leukocyte; Phosphodiesterase; Plasma; Reactive oxygen species

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE DEAMINASE; CHEMOATTRACTANT; CYCLIC AMP; FORMYLMETHIONYLLEUCYLPHENYLALANINE; OXYGEN RADICAL; PHOSPHODIESTERASE IV; REACTIVE OXYGEN METABOLITE;

ARTICLE; BINDING AFFINITY; CELL STIMULATION; CHEMOLUMINESCENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; RESPIRATORY BURST; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY;

ADENOSINE DEAMINASE; CHEMOTACTIC FACTORS; CYCLIC AMP; FREE RADICALS; HUMANS; LUMINESCENCE; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; REACTIVE OXYGEN SPECIES; RECEPTOR, ADENOSINE A1; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY;

EID: 77951938663     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2009.12.004     Document Type: Article

References (32)

1. Antonioli L., Fornai M., Colucci R., Ghisu N., Da Settimo F., Natale G., Kastsiuchenka O., Duranti E., Virdis A., Vassalle C., La Motta C., Mugnaini L., Breschi M.C., Blandizzi C., Del Taca M. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J. Pharmacol. Exp. Ther 2007, 322:435-442.
2. Brown J.B., Lee G., Grimm G.R., Barrett T.A. Therapeutic benefit of pentostatin in severe IL-10-/- colitis. Inflamm. Bowel. Dis. 2008, 14:880-887.
3. Bengtsson T., Zalavary S., Stendahl O., Grenegard M. Release of oxygen metabolites from chemoattractant-stimulated neutrophils is inhibited by resting platelets: role of extracellular adenosine and actin polymerization. Blood 1996, 87:4411-4423.
4. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. 1968, (Suppl, 97):77-89.
5. Cavalcante I.C., Castro M.V., Barreto A.R., Sullivan G.W., Vale M., Almeida P.R., Linden J., Rieger J.M., Cunha F.Q., Guerrant R.L., Ribeiro R.A., Brito G.A. Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect. Immun. 2006, 74:2606-2612.
6. Cave A.C., Brewer A.C., Narayanapanicker A., Ray R., Grieve D.J., Walker S., Shah A.M. NADPH oxidases in cardiovascular health and disease. Antioxid. .Redox. Signal. 2006, 8:691-728.
7. Chavan V., Patil N., Karnik N.D. Study of leukocytic hydrolytic enzymes in patients with acute stage of coronary heart disease. Indian. J. Med. Sci. 2007, 61:73-82.
8. Ciruela F., Saura C., Canela E.I., Mallol J., Lluis C., Franco R. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 1996, 380:219-223.
9. Cotter G., Dittrich H.C., Weatherley B.D., Bloomfield D.M., O'Connor C.M., Metra M., Massie B.M. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J. Card. Fail. 2008, 14:631-640.
10. Cronstein B.N. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 1994, 76:5-13.
11. Cronstein B.N., Kramer S.B., Weissmann G., Hirschhorn R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J. Exp. Med. 1983, 158:1160-1177.
12. Eltzschig H.K., Macmanus C.F., Colgan S.P. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends. Cardiovasc. Med. 2008, 18:103-107.
13. Eltzschig H.K., Weissmuller T., Mager A., Eckle T. Nucleotide metabolism and cell-cell interactions. Methods. Mol. Biol. 2006, 341:73-87.
14. Giusti G., Galanti B. Colorimetric method. Methods of Enzymatic Analysis 1984, 315-323. Verlag Chemie, Weinheim. B. HU (Ed.).
15. Hasko G., Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J. Leukoc. Biol. 2008, 83:447-455.
16. Hayes E.S. Adenosine receptors and cardiovascular disease: the adenosine-1 receptor (A1) and A1 selective ligands. Cardiovasc. Toxicol. 2003, 3:71-88.
17. Klockars M., Kleemola M., Leinonen M., Koskela M. Serum adenosine deaminase in viral and bacterial pneumonia. Chest. 1991, 99:623-626.
18. Lorenowicz M.J., Fernandez-Borja M., Hordijk P.L. cAMP signaling in leukocyte transendothelial migration. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1014-1022.
19. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis. Biochem. Soc. Trans. 2003, 31:1059-1061.
20. Lubos E., Handy D.E., Loscalzo J. Role of oxidative stress and nitric oxide in atherothrombosis. Front. Biosci. 2008, 13:5323-5344.
21. Nadeem A., Obiefuna P.C., Wilson C.N., Mustafa S.J. Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. Eur. J. Pharmacol. 2006, 551:116-124.
22. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 2006, 6:173-182.
23. Ottonello L., Morone M.P., Dapino P., Dallegri F. Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin. Exp. Immunol. 1995, 101:502-506.
24. Quinn K., Henriques M., Parker T., Slutsky A.S., Zhang H. Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. Am J Physiol.Heart. Circ. Physiol. 2008, 295:1817-1824.
25. Sari R.A., Taysi S., Yilmaz O., Bakan N. Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol. 2003, 21:87-90.
26. Saura C.A., Mallol J., Canela E.I., Lluis C., Franco R. Adenosine deaminase and A1 adenosine receptors internalize together following agonist-induced receptor desensitization. J. Biol. Chem. 1998, 273:17610-17617.
27. Slawsky M.T., Givertz M.M. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Expert. Opin. Pharmacother. 2009, 10:311-322.
28. Sun C.X., Zhong H., Mohsenin A., Morschl E., Chunn J.L., Molina J.G., Belardinelli L., Zeng D., Blackburn M.R. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Invest. 2006, 116:2173-2182.
29. Tuon F.F., Litvoc M.N., Lopes M.I. Adenosine deaminase and tuberculous pericarditis--a systematic review with meta-analysis. Acta. Trop. 2006, 99:67-74.
30. Valko M., Rhodes C.J., Moncol J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160:1-40.
31. Weber C., Zernecke A., Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol. 2008, 8:802-815.
32. Yegutkin G.G. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim. Biophys. Acta. 2008, 1783:673-694.